title: Pharmacokinetics - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 237/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Pharmacokinetics:
  In symptomatic newborns with CMV, the mean elimination half-life of ganciclovir was 2.4 hours.4 A target AUC12 (area under the concentration-time curve over a 12-h period) of 27 mg x h/L has been defined.5 The clearance of intravenous ganciclovir nearly doubled and the AUC12 was reduced by almost one-half during the first 6 weeks of life.5 Based on these data, it appears ganciclovir 6 mg/kg every 12 hours may be insufficient to achieve the pharmacokinetic target despite evidence for clinical and virological efficacy.5
  A pharmacokinetic study showed that oral valganciclovir 16 mg/kg every 12 hours achieved similar concentrations to IV ganciclovir 6 mg/kg every 12 hours. 5 [LOE III, GOR B]
  |
  |
  | |